As of April 15, 2025, UCB (UCB.VI) has a market cap of $30.04 billion USD. According to our data, UCB is ranked No.640 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 15, 2025 | $30.04 B |
-26.89%
|
Dec 30, 2024 | $41.09 B |
145.97%
|
Dec 29, 2023 | $16.70 B |
7.23%
|
Dec 30, 2022 | $15.58 B |
-25.26%
|
Dec 30, 2021 | $20.84 B |
20.08%
|
Dec 30, 2020 | $17.36 B |
20.83%
|
Dec 30, 2019 | $14.37 B |
4.29%
|
Dec 31, 2018 | $13.78 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
![]() USA
|
![]() Amgen
AMGN
|
$158.77 B |
0.132 B
|
![]() USA
|
![]() Biogen
BIIB
|
$17.12 B |
0.000 M
|
![]() USA
|
![]() Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
![]() USA
|
![]() Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
![]() USA
|
![]() GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
![]() UK
|
![]() Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
![]() USA
|
![]() Merck
MRK
|
$197.26 B |
0.003 M
|
![]() USA
|
![]() Novartis
NVS
|
$217.12 B |
0.003 M
|
![]() Switzerland
|
![]() Pfizer
PFE
|
$127.27 B |
-0.003 M
|
![]() USA
|
![]() Sanofi
SNY
|
$123.58 B |
-0.002 M
|
![]() France
|
![]() Takeda Pharmaceutical
TAK
|
$45.76 B |
0.002 M
|
![]() Japan
|
![]() Teva Pharmaceutical Industries
TEVA
|
$15.60 B |
0.000 M
|
![]() Israel
|
Market Cap | = | UCB.VI Stock Price | * | UCB.VI Shares Outstanding |
= | $158.08 | * | 0.19 B | |
= | $30.04 B |